UCB presented data from a Phase 1b study of UCB0599, an oral compound that suppresses alpha-synuclein misfolding, at the American Association of Neurology meeting in April.
Dr. Timothy Prestley, Founder & Director of Novus Neurology & TMS in Tuscaloosa, Alabama, was interviewed this week live on ABC’s Talk of Alabama morning show.
Aptinyx, Inc. was forced to suspend its study of NYX-458—a treatment for cognitive impairment in Parkinson’s disease (PD) and dementia with Lewy bodies (DLB)—due to the COVID-19 pandemic. Last week the biopharmaceutical company announced that they’ll again start screening patients for their Phase 2 study.
CND Life Sciences continues to build its presence as an exciting medical technology start-up. Phoenix Business Journal published a profile of the company this week along with the news of its freshly completed $2.4 million seed funding round.
By identifying potential genetic causes of Lewy body dementia (LBD), researchers hope to gain a better understanding of the devastating neurodegenerative disorder, for which there are no treatments. It is already known that LBD, Parkinson’s disease (PD), and Alzheimer’s disease (AD) are all caused by clumps of proteins that build up in the nerve cells of the brain (alpha-synuclein in LBD and PD, tau in AD). The three diseases have some overlapping symptoms and related features of neurodegeneration.
Although some symptoms of Parkinson’s disease (PD) can be controlled by medication, the hope of researchers, patients, and clinicians is that we can discover a treatment that can stop or reverse the course of PD and eventually find a cure. Central to developing disease-modifying treatments is an understanding of the role of alpha-synuclein, a key protein found in everyone’s brain, that’s recognized as a cause of PD.
Alterity Therapeutics announced that it has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research to continue its study of ATH434, a small molecule that targets alpha-synuclein, in Parkinson’s disease (PD).
Parkinson’s is a complicated neurological disorder that researchers are continuously working to understand. However, a lack of dopamine—a neurotransmitter responsible for our ability to control the way our bodies move (among many other things)—is widely recognized as a cause.
Recently, a team of researchers based in Israel evaluated whether certain proteins, known as bone morphogenetic proteins 5 and 7 (BMP5/7), could protect dopamine-producing neurons in the brains of mice from damage caused by the misfolded alpha-synuclein protein, another major player in the cause of Parkinson’s disease.
The researchers found that not only did BMP5/7 reverse the alpha-synuclein-induced loss of dopamine-producing neurons, but it also reduced the accumulation of alpha-synuclein in the brain and prevented motor impairment in the study mice. The authors conclude that BMPs are a promising option in the development of disease-modifying treatments for Parkinson’s, an area of significant unmet need.